

Clinical Policy: Insulin Glargine (Basaglar, Lantus, Rezvoglar, Semglee)

Reference Number: CP.CPA.228

Effective Date: 03.01.17

Last Review Date: 02.26

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Insulin glargine (Basaglar[®], Lantus^{®*}, Rezvoglar[™], Semglee^{®†}) is a long-acting human insulin analog.

**For California and Oregon Commercial plans, Lantus does not require prior authorization; these criteria do not apply.*

†For California Exchange plans, insulin glargine-yfgn (unbranded Semglee) does not require prior authorization; these criteria do not apply.

FDA Approved Indication(s)

Rezvoglar and Semglee are indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Basaglar is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Lantus is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Limitation(s) of use: These products are not recommended for the treatment of diabetic ketoacidosis.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Basaglar, Lantus, Rezvoglar, and Semglee are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Diabetes Mellitus (must meet all):

1. Diagnosis of type 1 or type 2 diabetes mellitus;
2. One of the following (a or b):
 - a. For California Exchange plans only: Failure of all the following, unless clinically significant adverse effects are experienced or all are contraindicated: insulin glargine-yfgn (unbranded Semglee), Toujeo[®], Tresiba[®];

- b. For California and Oregon Commercial plans only: Failure of all the following, unless clinically significant adverse effects are experienced or all are contraindicated: Lantus*, Toujeo, Tresiba.

**For California and Oregon Commercial Plans, Lantus SoloStar (NDC 00088221901) is non-formulary. Refer to the formulary exception policy, CP.CPA.190.*

Approval duration: 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. Diabetes Mellitus (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. One of the following (a or b):
 - a. For California Exchange plans only: Failure of all the following, unless clinically significant adverse effects are experienced or all are contraindicated: insulin glargine-yfgn (unbranded Semglee), Toujeo, Tresiba;
 - b. For California and Oregon Commercial plans only: Failure of all the following, unless clinically significant adverse effects are experienced or all are contraindicated: Lantus*, Toujeo, Tresiba.
**For California and Oregon Commercial Plans, Lantus SoloStar (NDC 00088221901) is non-formulary. Refer to the formulary exception policy, CP.CPA.190.*

Approval duration: 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Lantus, Toujeo (insulin glargine) and insulin glargine-yfgn (unbranded Semglee)	<p>Type 1 diabetes mellitus: Approximately one-third of the total daily insulin requirement SC QD</p> <p>Type 2 diabetes mellitus: 0.2 units/kg SC QD or 10 units/day initially. Adjust dosage according to patient response</p>	Not applicable
Tresiba (insulin degludec)	<p>Type 1 diabetes mellitus:</p> <p>Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 1/3 to 1/2 of total daily insulin dose SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Adults: same unit dose as total daily long or intermediate-acting insulin unit dose ○ Pediatrics: 80% of total daily long or intermediate-acting insulin unit dose 	Not applicable

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	Type 2 diabetes mellitus: Initiation: <ul style="list-style-type: none"> • Insulin-naïve: 10 units SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Adults: same unit dose as total daily long or intermediate-acting insulin unit dose ○ Pediatrics: 80% of total daily long or intermediate-acting insulin unit dose 	

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Use during episodes of hypoglycemia
 - Hypersensitivity to insulin glargine products or of its excipients
- Boxed warning(s): none reported

Appendix D: General Information

- If changing patients from another insulin glargine 100 units/mL product (e.g., Lantus) to Basaglar, the dose of Basaglar should be the same as the other insulin glargine product.
- If changing patients from a once-daily insulin glargine 300 units/mL product (e.g., Toujeo) to once-daily Basaglar, Rezvoglar, or Semglee/insulin glargine-yfgn, the recommended initial dosage is 80% of the insulin glargine product dose that is being discontinued.
- Semglee and insulin glargine-yfgn are considered to be interchangeable with Lantus.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Type 1 diabetes mellitus	Initiation: Approximately one-third of the total daily insulin requirement administered SC QD	Not applicable
Type 2 diabetes mellitus	Initiation: 0.2 units/kg SC QD or 10 units/day. Adjust dosage according to patient response	Not applicable

VI. Product Availability

Drug Name	Availability
Insulin glargine (Basaglar)	KwikPen [®] prefilled delivery device: 3 mL containing 100 units/mL TempoPen [™] prefilled delivery device: 3 mL containing 100 units/mL
Insulin glargine (Lantus)	Multiple-dose vial: 10 mL containing 100 units/mL Lantus SoloStar prefilled pen: 3 mL containing 100 units/mL
Insulin glargine-aglr (Rezvoglar)	KwikPen [®] prefilled pen: 3 mL containing 100 units/mL

Drug Name	Availability
Insulin glargine-yfgn (Semglee)*	Multiple-dose vial: 10 mL containing 100 units/mL Prefilled pen: 3 mL containing 100 units/mL

*Available generically

VII. References

1. Basaglar Prescribing Information. Indianapolis, IN: Eli Lilly and Company; July 2021. Available at: www.basaglar.com. Accessed July 15, 2025.
2. Lantus Prescribing Information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; June 2023. Available at: www.lantus.com. Accessed July 15, 2025.
3. Semglee Prescribing Information. Morgantown, WV: Mylan Specialty L.P.; March 2025. Available at: www.semglee.com. Accessed July 15, 2025.
4. Insulin Glargine-yfgn Injection Prescribing Information. Morgantown, WV: Mylan Specialty L.P.; November 2023. Available at: <https://www.semglee.com>. Accessed July 16, 2024.
5. Toujeo Prescribing Information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2023. Available at: <https://products.sanofi.us/Toujeo/Toujeo.pdf>. Accessed July 15, 2025.
6. Tresiba Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.; July 2022. Available at: www.tresiba.com. Accessed July 15, 2025.
7. Rezvoglar Prescribing Information. Indianapolis, IN: Eli Lilly and Company; August 2024. Available at: <https://pi.lilly.com/us/rezvoglar-uspi.pdf>. Accessed July 15, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2021 annual review: no significant changes; references reviewed and updated.	06.28.21	11.21
RT4: added Rezvoglar to policy.	01.10.22	
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.	04.26.22	08.22
4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section.	07.18.22	11.22
RT4: updated FDA approved indications for Rezvolar to include pediatric extension in type 2 diabetes mellitus.	12.07.22	
4Q 2023 annual review: no significant changes; updated Semglee indication language to align with prescriber information; references reviewed and updated.	06.26.23	11.23
Per September SDC: removed redirection to Levemir [®] ; added clarification under initial approval criteria for Lantus redirection “For California and Oregon Commercial Plans, Lantus SoloStar (NDC 00088221901) is non-formulary. Refer to the formulary exception policy, CP.CPA.190”; removed Levemir from Appendix B.	09.21.23	12.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2024 annual review: revised approval duration from “12 months or duration of request, whichever is longer” to standard injectable agent duration of “6 months or to the member’s renewal date, whichever is longer”; references reviewed and updated.	07.30.24	11.24
Per September SDC: for California Exchange plans, added redirection to Semglee (as an additional step along with Toujeo and Tresiba) and removed redirection to Lantus; clarified existing redirection to Lantus, Toujeo, and Tresiba apply to California and Oregon Commercial plans only; added Lantus to criteria; under criteria description for California and Oregon Commercial plans, added exception statements that Lantus does not require prior authorization; for California Exchange plans, added exception statement that Semglee does not require prior authorization.	09.25.24	12.24
4Q 2025 annual review: no significant changes; references reviewed and updated.	07.17.25	11.25
Per SDC, under criteria description for California Exchange plans, clarified exception statement that <i>insulin glargine-yfjn (unbranded Semglee)</i> does not require prior authorization	12.18.25	02.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a

discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.